Home/Filings/4/0000950170-24-106978
4//SEC Filing

George Simeon 4

Accession 0000950170-24-106978

CIK 0001953926other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 8:51 PM ET

Size

23.0 KB

Accession

0000950170-24-106978

Insider Transaction Report

Form 4
Period: 2024-09-16
George Simeon
10% Owner
Transactions
  • Conversion

    Series C Convertible Preferred Stock

    2024-09-164,357,1460 total(indirect: See Note 3)
    Common Stock (501,796 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2024-09-165,809,5280 total(indirect: See Note 4)
    Common Stock (669,061 underlying)
  • Purchase

    Common Stock

    2024-09-16$17.00/sh+1,352,942$23,000,0141,854,738 total(indirect: See Note 3)
  • Conversion

    Common Stock

    2024-09-16+501,796501,796 total(indirect: See Note 3)
  • Purchase

    Common Stock

    2024-09-16$17.00/sh+441,176$7,499,9921,110,237 total(indirect: See Note 4)
  • Conversion

    Series C Convertible Preferred Stock

    2024-09-1613,071,4390 total(indirect: See Note 2)
    Common Stock (1,505,388 underlying)
  • Purchase

    Common Stock

    2024-09-16$17.00/sh+441,176$7,499,9921,946,564 total(indirect: See Note 2)
  • Conversion

    Common Stock

    2024-09-16+669,061669,061 total(indirect: See Note 4)
  • Conversion

    Common Stock

    2024-09-16+1,505,3881,505,388 total(indirect: See Note 2)
Transactions
  • Conversion

    Series C Convertible Preferred Stock

    2024-09-1613,071,4390 total(indirect: See Note 2)
    Common Stock (1,505,388 underlying)
  • Purchase

    Common Stock

    2024-09-16$17.00/sh+441,176$7,499,9921,110,237 total(indirect: See Note 4)
  • Purchase

    Common Stock

    2024-09-16$17.00/sh+441,176$7,499,9921,946,564 total(indirect: See Note 2)
  • Conversion

    Common Stock

    2024-09-16+501,796501,796 total(indirect: See Note 3)
  • Conversion

    Common Stock

    2024-09-16+669,061669,061 total(indirect: See Note 4)
  • Conversion

    Series C Convertible Preferred Stock

    2024-09-164,357,1460 total(indirect: See Note 3)
    Common Stock (501,796 underlying)
  • Purchase

    Common Stock

    2024-09-16$17.00/sh+1,352,942$23,000,0141,854,738 total(indirect: See Note 3)
  • Conversion

    Common Stock

    2024-09-16+1,505,3881,505,388 total(indirect: See Note 2)
  • Conversion

    Series C Convertible Preferred Stock

    2024-09-165,809,5280 total(indirect: See Note 4)
    Common Stock (669,061 underlying)
Footnotes (4)
  • [F1]On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
  • [F2]The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Partners II, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners II, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
  • [F3]The reported securities are held directly by AMZL, LP. SR One Capital SMA Partners, LP is the general partner of AMZL, LP, and SR One Capital Management, LLC is the general partner of SR One Capital SMA Partners, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital SMA Partners, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
  • [F4]The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Opportunities Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Opportunities Partners I, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Documents

1 file

Issuer

Zenas BioPharma, Inc.

CIK 0001953926

Entity typeother

Related Parties

1
  • filerCIK 0001595117

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 8:51 PM ET
Size
23.0 KB